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OBJECTIVES: With advances in blood ketone testing
methodology, diabetic patients can now monitor the pre-
dominant ketone body (beta-hydroxybutyrate) at home
in addition to their standard glucose monitoring. This
ketone monitoring may permit early detection and treat-
ment of ketosis and diabetic ketoacidosis (DKA). This
study compares the cost consequences of blood vs. urine
ketone testing and of optimal vs. normal glycemic control
in diabetes management.
METHODS: First, a decision tree model was developed
to estimate costs of testing ketone levels and managing
acute metabolic complications for patients with insulin
dependent diabetes mellitus (IDDM). Home blood ketone
testing or urine ketone testing was utilized during
patients’ sick-day management. Second, a Markov
process was applied to project progression of diabetic
complications based on HbA1c levels over 5 years using
the published Diabetes Control and Complications Trial
data. Cost analyses in 2001 U.S. dollars were performed
from the payer’s perspective using data from published
literature and applying a 3% discount rate. Assumptions
were tested in one-way sensitivity analyses.
RESULTS: In the base case, the decision tree model
showed that blood ketone testing could prevent 7.2 DKA
events per 1,000 IDDM patients per year, yielding a net
savings of $51,982 compared to urine ketone testing,
mainly due to reduced medical care costs for treating
DKA, ketosis and hypoglycemia. In addition, the Markov
model predicted that over 5 years, improved glycemic
control as shown by lowered HbA1c levels from 9% to
7% could save $253,322 per 1,000 IDDM patients for
treating diabetic complications, including $69,116 for
retinopathy, $122,762 for nephropathy, and $61,444 
for neuropathy. The results were robust in sensitivity
analyses.
CONCLUSIONS: Under a range of assumptions blood
ketone testing could reduce ketosis and DKA events,
thereby lowering medical expenditures. Potentially
improved glycemic control through lowered HbA1c levels
could decrease treatment costs for long-term diabetic
complications.
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OBJECTIVE: To assess the direct medical cost of treat-
ment, from a payer perspective, associated with the ﬁrst
three years of care for patients newly diagnosed with type
2 diabetes, and to contrast the costs and effectiveness
associated with six commonly prescribed ﬁrst-line oral
antidiabetic medications.
METHODS: A literature-based, decision tree cohort
model was developed to project the number of patients
achieving hemoglobin A1c < 7% on oral therapies and
the associated costs over a three-year timeframe. Drug
naïve patients could progress in a step-wise fashion to
triple oral therapy prior to the introduction of insulin.
The overall cost of treatment included ofﬁce visits, 
laboratory tests, education, drug therapy, home glucose
monitoring, and treatment of adverse events. To account
for uncertainty in the model parameters, we conducted
probabilistic sensitivity analysis via second order Monte
Carlo simulation, assuming triangular distributions for
the variables.
RESULTS: Mean per patient cost of treatment (range:
2.5–97.5 percentiles of all model runs) was $6,391
($5,150–$7,736) for glipizide GITS (Glucotrol XL),
$6,774 ($5,594–$7,978) for metformin extended release
(Glucophage XR), $7,034 ($5,754–$8,295) for gly-
buride/metformin (Glucovance), $7,068 ($5,782–$8,312)
for metformin immediate release (Glucophage), $7,924
($6,688–$9,194) for rosiglitazone (Avandia), and $8,793
($7,123–$10,464) for repaglinide (Prandin). Regardless
of ﬁrst-line therapy selected, patients progressed quickly
to combination therapies to achieve glycemic control,
with effectiveness among the strategies being similar. 
In 73–99% of the model simulations, the glipizide GITS
ﬁrst-line strategy was cost saving compared to the other
ﬁrst-line strategies.
CONCLUSIONS: The short-term costs required to
provide comprehensive diabetes care and achieve recom-
mended glycemic goals can be substantial. Our model
suggests that a glipizide GITS strategy may provide
similar effectiveness with a high likelihood of cost savings
versus ﬁve other ﬁrst-line agents and should be considered
when selecting an initial drug therapy in type 2 diabetes.
